Amlodipine (versus unexposed)

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17247
R72177		 Vaclavik, 2024 Low birth weight during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 3.39 [2.69;4.28] -/87   -/66,393 - 87
ref
S14425
R57261		 Mito, 2019 Low birth weight (<2500 g) at least 1st trimester retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only chronic hypertension indication 0.54 [0.26;1.15] C 12/48   49/129 61 48
ref
Total 2 studies 1.41 [0.23;8.44] 61 135
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik, 2024Vaclavik, 2024 3.39[2.69; 4.28]-8752%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Mito, 2019Mito, 2019 0.54[0.26; 1.15]614848%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 95% 1.41[0.23; 8.44]611350.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.41[0.23; 8.44]6113595%NAVaclavik, 2024 Mito, 2019 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 3.39[2.69; 4.28]-87 -NAVaclavik, 2024 1 unexposed, sickunexposed, sick 0.54[0.26; 1.15]6148 -NAMito, 2019 1 Tags Adjustment   - No  - No 1.41[0.23; 8.44]6113595%NAVaclavik, 2024 Mito, 2019 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 3.39[2.69; 4.28]-87 -NAVaclavik, 2024 1   - Only chronic hypertension indication  - Only chronic hypertension indication 0.54[0.26; 1.15]6148 -NAMito, 2019 1 All studiesAll studies 1.41[0.23; 8.44]6113595%NAVaclavik, 2024 Mito, 2019 20.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 3.39[2.69; 4.28]-87 -NAVaclavik, 2024 1 unexposed, sick controlsunexposed, sick controls 0.54[0.26; 1.15]6148 -NAMito, 2019 10.510.01.0